Literature DB >> 26514520

Clinicopathological Significance of DLC-1 Expression in Cancer: a Meta-Analysis.

Yan Jiang1, Jian-Ming Li, Huai-Qing Luo.   

Abstract

BACKGROUND: Recent reports have shown that DLC-1 is widely expressed in normal tissues and is down- regulated in a wide range of human tumors, suggesting it may act as a tumor suppressor gene. We conducted a meta-analysis to determine the correlation between DLC-1 expression and clinicopathological characteristics in cancers.
MATERIALS AND METHODS: A detailed literature search was made for relevant publications from PubMed, EMBASE, Cochrane library databases, Web of Science, CNKI. The methodological quality of the studies was also evaluated. Analyses of pooled data were performed and odds ratios (ORs) were calculated and summarized.
RESULTS: Final analysis was performed of 1,815 cancer patients from 19 eligible studies. We observed that DLC- 1 expression was significantly lower in cancers than in normal tissues. DLC-1 expression was not found to be associated with tumor differentiation status. However, DLC-1 expression was obviously lower in advance stage than in early-stage cancers and was more down-regulated in metastatic than non-metastatic cancers.
CONCLUSIONS: The results of our meta-analysis suggested that DLC-1 expression is significantly lower in cancers than in normal tissues. Aberrant DLC-1 expression may play an important role in cancer genesis and metastasis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26514520     DOI: 10.7314/apjcp.2015.16.16.7255

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

Review 1.  Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Authors:  Nana Zheng; Zhiwei Wang; Wenyi Wei
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

2.  Downregulation of STARD8 in gastric cancer and its involvement in gastric cancer progression.

Authors:  Shuanglong Zhang; Xiaojing Chang; Jinguo Ma; Jing Chen; Yu Zhi; Zhenhua Li; Dongqiu Dai
Journal:  Onco Targets Ther       Date:  2018-05-21       Impact factor: 4.147

3.  Inhibition of miR-141 and miR-200a Increase DLC-1 and ZEB2 Expression, Enhance Migration and Invasion in Metastatic Serous Ovarian Cancer.

Authors:  Norhazlina Abdul Wahab; Zahreena Othman; Noor Wahidah Mohd Nasri; Mohd Helmy Mokhtar; Siti Fatimah Ibrahim; Adila A Hamid; Raja Affendi Raja Ali; Norfilza Mohd Mokhtar
Journal:  Int J Environ Res Public Health       Date:  2020-04-17       Impact factor: 3.390

4.  Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3'-Untranslated Region of DLC1.

Authors:  Sheril June Ankasha; Mohamad Nasir Shafiee; Norhazlina Abdul Wahab; Raja Affendi Raja Ali; Norfilza Mohd Mokhtar
Journal:  Int J Environ Res Public Health       Date:  2021-05-27       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.